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Locally advanced upper tract urothelial carcinoma has a poor prognosis. While surgery represents the only potentially curable
therapeutic intervention, recurrences are common and typically systemic in nature. It is thus reasonable to consider perioperative
chemotherapy in an eﬀort to decrease the risk of recurrence. There are very little direct data providing clinical guidance in this
scenario. For urothelial cancer of the bladder, there are randomized phase III data demonstrating a survival advantage with
neoadjuvant cisplatin-based combination chemotherapy. Although arguments favoring adjuvant chemotherapy could be made
for upper tract urothelial cancer, the loss of renal function that occurs with nephrectomy can complicate administration of
appropriate perioperative treatment. Therefore, by analogy to urothelial carcinoma of the lower tract, it is argued that cisplatin-
based neoadjuvant chemotherapy should be the standard of care for patients with locally advanced upper tract urothelial cancer.
Copyright © 2009 P. H. O’Donnell and W. M. Stadler. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Locally advanced upper tract urothelial carcinoma has a
poor prognosis. Surgical series suggest that, notwithstanding
nodal status, the disease-speciﬁc ﬁve-year survival rates for
stages T2 and T3 disease are 73% and 40%, respectively,
while the median survival for T4 patients is approximately
6 months [1]. Importantly, the vast majority of patients
with invasive upper tract urothelial carcinoma have stage
T3 or greater disease at the time of surgery [2, 3], and,
if investigated, at least 20–25% will have lymph node
involvementatthetimeofsurgery[4–6].Thepoorprognosis
is furthermore reﬂected by mortality estimates in which
the mortality to incidence ratio for upper tract disease is
approximately 0.34 [7], whereas for lower tract urothelial
cancer it is 0.20 [8]. This may be due in part to the notorious
diﬃculty of diagnosing earlier-stage urothelial cancer of the
upper tract.
The most common presenting symptom of upper tract
urothelial carcinoma, like its bladder counterpart, is hema-
turia [1]. Unfortunately, urine cytology is not particularly
sensitive for diagnosing urothelial carcinoma of any loca-
tion [9, 10]. Anterior grade and retrograde pyelogram,
or ureteroscopy with visualization of the renal pelvices,
are technically challenging and not routinely performed in
the evaluation of hematuria. Computed tomography (CT)
imaging is also not very sensitive for early stage disease
[11, 12].
While surgery represents the only potentially curable
therapeutic intervention for upper tract urothelial cancer,
systemic recurrences are common [1, 3, 13]. It is thus
reasonable to consider perioperative chemotherapy in an
eﬀort to decrease the risk of recurrence. Unfortunately,
with only approximately 2000 cases annually in the United
States [7, 14], and with the historical diﬃculties in accruing
urothelial carcinoma patients to clinical trials, there are very
little direct data providing clinical guidance in this scenario.
Using analogy to urothelial carcinoma of the lower tract,
we believe that cisplatin-based neoadjuvant chemotherapy
should be the standard of care for patients with locally
advanced upper tract urothelial cancer.
2. Is Urothelial Cancer of the Upper
Tract Different?
Bladder and upper tract urothelial carcinomas have tradi-
tionally been considered separate diseases in the urologic
and surgical literature mainly because the surgical approach2 Advances in Urology
to these diseases is so diﬀerent. Yet, recent evidence has
suggested that the anatomic location of disease has no
bearing on tumor behavior, in that recurrence and mortality
rates from upper and lower tract carcinomas are similar
when adjusted for tumor stage and grade [15]. Additionally,
from a biologic prospective, there is very little diﬀerence
between urothelial carcinomas that arise from these diﬀerent
sites. First of all, the most important epidemiologic risk
factor for urothelial cancer remains exposure to tobacco
products [16, 17], and this is true regardless of the site of
origin. Secondly, the urothelial tissue itself is histologically
indistinguishable by site [18]. Certainly, there are diﬀerences
in the underlying stroma and supportive tissue, but the
importance of these diﬀerences in the treatment of systemic
disease, including the microscopic systemic disease that
is being targeted in perioperative therapy, is debatable.
Thirdly, the molecular oncogenic events appear to be the
same between upper and lower tract urothelial cancers.
For example, for both origins, chromosome 9 deletions
are the most common genetic abnormality [19, 20], and
chromosome 9 and p53 alterations appear to be present at
similar frequencies in upper and lower tract lesions [20, 21].
Fourth, it has been the practice of the medical oncology
community to include urothelial carcinoma patients in trials
of metastatic disease, regardless of the site of origin. A
number of large studies have thus included at least a fraction
of patients whose initial tumor began in the upper tract
[22–28]. In none of those studies was the site of origin
an important prognostic factor in the context of systemic
chemotherapy. Finally, the high incidence of secondary (40–
50%), or, less commonly, synchronous (8%) lower tract
disease in patients with upper tract disease [1, 29] also
supports the notion that these cancers actually represent
one disease process in such patients. It is thus reasonable
to consider systemic and perioperative chemotherapy for
locally advanced upper tract urothelial cancer by analogy to
urothelial cancer of the bladder.
For urothelial cancer of the bladder, there are ran-
domized phase III data demonstrating a survival advantage
with neoadjuvant cisplatin-based combination chemother-
apy. The two largest trials were conducted by an interna-
tional collaboration [30] and by Grossman et al. [31]. A
meta-analysis including all neoadjuvant chemotherapy trials
conﬁrms the conclusion [32]. Others have argued that the
absolute beneﬁt of neoadjuvant chemotherapy is modest
[33], and that the more accurate clinical staging aﬀorded by
surgery [34] allows better patient selection on the basis of
prognostic factors [35]. Under the assumption of equivalent
beneﬁt irrespective of underlying prognosis, the absolute
beneﬁt of perioperative chemotherapy for poor prognosis
patients is certainly going to be greater than that for good
prognosis patients. Nevertheless, the randomized studies of
adjuvant chemotherapy in urothelial cancer of the bladder
have been undersized and underpowered for detecting a
clinically signiﬁcant beneﬁt [36–40].
Although similar arguments favoring adjuvant chemo-
therapy could be made for upper tract urothelial cancer, the
loss of renal function that occurs with nephrectomy can fur-
ther complicate administration of appropriate perioperative
treatment. In this regard, the above noted meta-analysis [32]
demonstrated survival beneﬁts with neoadjuvant therapy
only when cisplatin-based combination chemotherapy was
utilized, and two randomized studies in the metastatic
setting have strongly suggested that carboplatin, which is
typically substituted for cisplatin in patients with renal
dysfunction, is an inferior agent [41, 42]. Furthermore, the
decrement in renal function associated with nephrectomy is
not inconsequential, as evidenced by studies in renal cancer
patients undergoing nephrectomy [43, 44]. This may be even
more important in urothelial cancer patients who are often
smokers and have other smoking-related comorbidities.
Finally, anecdotal experience and early evidence [45, 46]
suggest that even among patients in whom neoadjuvant
chemotherapy is indicated, only a minority actually receive
chemotherapy.Thisraisesconcernsaboutalackofadherence
to chemotherapy recommendations [47] in the urologic
community, or perhaps an unwillingness by patients to
be treated. Even if some urologists forgo neoadjuvant
chemotherapy referral in favor of future adjuvant adminis-
tration, adherence percentages in the postoperative setting
are likely to be even lower, because of both patient and
surgeon factors [48, 49]. Furthermore, despite hypothetical
concernsaboutthepotentialforincreasedsurgicalmorbidity
after neoadjuvant chemotherapy, the data in bladder cancer
patients have strongly demonstrated that this does not occur
[49, 50], so we anticipate that the same would be true for
neoadjuvant chemotherapy in upper tract disease.
3. Conclusions
Upper tract urothelial carcinoma, when not metastatic,
typically presents with locally advanced disease. Such disease
has a poor prognosis because of the high risk of systemic
recurrence. Although the surgical approach to upper tract
and lower tract urothelial cancers is markedly diﬀerent, the
biology of these diseases is for the most part indistinguish-
able. Certainly, the response to therapy appears to be the
same. Given the rarity of upper tract urothelial cancer and
the diﬃculty of accruing to clinical trials, recommendations
for perioperative chemotherapy must currently be based on
similarities to its lower tract counterpart. In this regard,
neoadjuvant chemotherapy is the standard of care based on
improvements in survival in well-conducted phase III trials.
Such data does not exist with adjuvant therapy in bladder
cancer,andadjuvanttherapyforuppertractdiseaseisfurther
complicated by the diﬃculty of administering cisplatin-
based regimens to patients who may suﬀer a decrement
in renal function following nephrectomy. Therefore, until
and unless speciﬁc trials are conducted, the most reasonable
standard for locally advanced upper tract urothelial cancer
is neoadjuvant, cisplatin-based combination chemotherapy
prior to nephrectomy and surgical resection.
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